---
title: "ANI Pharmaceuticals to Discuss Second Quarter 2026 Financial Results on August 7, 2026 at 8:00 a.m. ET | ANIP Stock News"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/293745096.md"
description: "ANI Pharmaceuticals announced it will release its second quarter 2026 financial results on August 7, 2026, at 8:00 a.m. ET. The company's leadership team, including CEO Nikhil Lalwani and CFO Stephen P. Carey, will host a webcast and conference call to discuss the findings. Access details are available on the company's investor relations website."
datetime: "2026-07-24T02:50:00.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/293745096.md)
  - [en](https://longbridge.com/en/news/293745096.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/293745096.md)
---

# ANI Pharmaceuticals to Discuss Second Quarter 2026 Financial Results on August 7, 2026 at 8:00 a.m. ET | ANIP Stock News

See more from StockTitan in Google Search and AI answers.Adds StockTitan as a preferred source · opens Google

Add on Google

PRINCETON, N.J., July 24, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced that the Company will release its second quarter 2026 financial results on Friday, August 7, 2026, at 8:00 a.m. ET.

Nikhil Lalwani, President and Chief Executive Officer, Stephen P. Carey, Senior Vice President, Finance, and Chief Financial Officer, and Chris Mutz, Head of Rare Disease will host a webcast and conference call to discuss the results.

To view the webcast, please click here. Links to access the webcast and conference call will also be available on the “Events & Presentations” page of the Company’s website at https://www.anipharmaceuticals.com, under the “Investors” section. A replay of the event will remain accessible for up to one year.

**About ANI**

ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) is a diversified biopharmaceutical company committed to its mission of “Serving Patients, Improving Lives" by developing, manufacturing, and commercializing innovative and high-quality therapeutics. The Company is focused on delivering sustainable growth through its Rare Disease business, which markets novel products in the areas of ophthalmology, rheumatology, nephrology, neurology, and pulmonology; its Generics business, which leverages R&D expertise, operational excellence, and U.S.-based manufacturing; and its Brands business. For more information, visit https://www.anipharmaceuticals.com.

**Investor Relations:**  
Irina Koffler, Vice President, Investor Relations  
T: 917-734-7387  
E: Irina.koffler@anipharmaceuticals.com

**Media Relations:**  
Argot Partners  
T: 212-600-1494  
E: ani@argotpartners.com

_SOURCE: ANI Pharmaceuticals, Inc._

### Related Stocks

- [ANIP.US](https://longbridge.com/en/quote/ANIP.US.md)

## Related News & Research

- [ANI Pharmaceuticals, Inc. $ANIP Shares Purchased by Arrowstreet Capital Limited Partnership](https://longbridge.com/en/news/294166812.md)
- [Renaissance Technologies LLC Sells 128,300 Shares of ANI Pharmaceuticals, Inc. $ANIP](https://longbridge.com/en/news/294579223.md)
- [Equatorial Energia updates financial calendar for 2026 disclosures](https://longbridge.com/en/news/294368263.md)
- [T-Mobile US sets Q3 2026 distribution at R$ 0.25 per unit, payable Sept. 16](https://longbridge.com/en/news/294251549.md)
- [Wallenius Wilhelmsen to present Q2 2026 results in webcast](https://longbridge.com/en/news/294691516.md)